Good evening :)
$
₹
Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

PTGX

NASDAQ
Asset Logo

Protagonist Therapeutics Inc

PTGX

NASDAQ
$135.735.32% (-7.63)
$
₹
$135.735.32% (-7.63)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $9.1B the stock is ranked 1028

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

136.15
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

10.71
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.03
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

29.4%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 14 analysts reports

Buy
14 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+24.55%

Earnings Growth

+332.54%

Rev. Growth

+1093.12%

See Detailed Forecast

Company Profile

Company Profile

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 24.55% growth, versus a trailing 3-year CAGR of 106.46%.

2026
Current$143.37Baseline
Analyst Target - 1 year
Target$178.57+24.55%

All values in $

202220232024202520262027$56.47$103.12$149.78Target+24.55%
2026
Current$143.37Baseline
Analyst Target - 1 year
Target$178.57+24.55%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 1093.12% growth, versus a trailing 3-year CAGR of 20.07%.

2025
Current$46.01Baseline
Forecast for Dec 2026
High$586.5+1174.56%
Average$549.02+1093.12%
Low$445.21+867.52%

All values in $ Million

20212022202320242025202627.3526.5860434.4346.01Low+867.52%Average+1093.12%High+1174.56%
2025
Current$46.01Baseline
Forecast for Dec 2026
High$586.5+1174.56%
Average$549.02+1093.12%
Low$445.21+867.52%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.05Baseline
Forecast for Dec 2026
High$5.74+380%
Average$4.77+332.54%
Low$3.52+271.88%

All values in $

202120222023202420252026-2.7-2.6-1.494.2-2.05Low+271.88%Average+332.54%High+380%
2025
Current$-2.05Baseline
Forecast for Dec 2026
High$5.74+380%
Average$4.77+332.54%
Low$3.52+271.88%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

4.7
-39.3
7.4
-44.3
56.3
3.7
213.4
162.8
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue254.954.164.67170.6328.325.544.717.4356.36213.47
Net Income207.34-30.61-33.21131.67-11.65-34.77-39.33-44.383.78162.84
Net Profit Margin81.32%-734.72%-710.37%77.16%-41.15%-626.95%-834.86%-596.79%6.71%76.28%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Protagonist Therapeutics Inc 136.1510.710
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PTGX with any stock or ETF
Compare PTGX with any stock or ETF
Comparing from
PTGX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Protagonist Therapeutics Inc (PTGX) share price today is $135.73 as of November 5, 2026 at 11:19 PM IST. The stock touched a day high of $142.35 and a day low of $135.45.

  2. Protagonist Therapeutics Inc stock trades on NASDAQ under the ticker symbol PTGX.

  3. Protagonist Therapeutics Inc's market capitalization is $9.07B as of November 5, 2026 at 11:19 PM IST.

  4. Protagonist Therapeutics Inc's price-to-earnings (P/E) ratio is 136.15 as of November 5, 2026.

  5. Protagonist Therapeutics Inc's price-to-book (P/B) ratio is 10.71 as of November 5, 2026.

  6. Yes, You can buy Protagonist Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Protagonist Therapeutics Inc shares in three steps: 1. Search Protagonist Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Protagonist Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Protagonist Therapeutics Inc (PTGX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0736 shares at the current price of $135.73.

Loading...